clinical research prime

Pneumococcal: Infants 42-89 Days Old

  • Phase 3 study to investigate the safety of a 21-valent pneumococcal conjugate vaccine in healthy infants, compared to Prevnar 20. 
  • Participants will receive study related prevention at no cost and will be compensated for time and travel.

Eligible participants must meet following criteria:

  • Child does not have any known underlying illnesses

  • Child does not have a hypersensitivity to any vaccines

  • Child has not participated in any research study prior